Drug Trial Radar · NCT03414034
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Aug 14, 2018
Primary completion
Oct 16, 2023
Study completion Oct 16, 2023
Sponsor
- Lead sponsor
- Cardiff OncologyIndustry
- Sponsor type
- Industry
- First posted
- Jan 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.
Conditions
- Metastatic Castration-Resistant Prostate Cancer
Interventions
OnvansertibDrug
Onvansertib orally
AbirateroneDrug
Abiraterone orally
PrednisoneDrug
Prednisone orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Disease Control at or Before 12 WeeksTime frame: Baseline up to Week 12
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.